Evidence map›Paper›PMID 34413199›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2021

Influence of Contingent and Noncontingent Drug Histories on the Development of High Levels of MDPV Self-Administration.

Michelle R Doyle, Agnieszka Sulima, Kenner C Rice, Gregory T Collins

Abstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Michelle R DoyleDepartment of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.).
Agnieszka SulimaDepartment of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.).
Kenner C RiceDepartment of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.).
Gregory T CollinsDepartment of Pharmacology, The University of Texas Health Science Center at San Antonio, San Antonio, Texas (M.R.D., G.T.C.); South Texas Veterans Health Care System, San Antonio, Texas (M.R.D., G.T.C.); and Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch, NIDA and NIAAA, Bethesda, Maryland (A.S., K.C.R.) CollinsG@uthscsa.edu.

Funding

Bath Salts: Abuse-related and Toxic EffectsR01DA039146 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Gregory Collins · 2015 to 2026
$4.0M
Integrated Graduate Training Program in Neuroscience, UTHSCSAT32NS082145 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI David A Morilak · 2013 to 2026
$1.5M
Role of dopamine D3 and serotonin 2C receptors in the development of an addiction-like phenotype in ratsR36DA050955 · NIDA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DOYLE, MICHELLE RIANE · 2020 to 2021
$108k
NIDA NIH HHS R01 DA039146NIDA NIH HHS R36 DA050955NINDS NIH HHS T32 NS082145
6 · The paper itself

Abstract

A subset of rats that self-administer 3,4-methylenedioxypyrovalerone (MDPV) develop unusually high levels of drug taking. A history of responding maintained by cocaine, but not food, prevents the development of this high-responder phenotype; however, it is unclear how histories of noncontingent cocaine exposure or self-administering drugs from other pharmacological classes would affect its development. In the current studies, 5 groups of male Sprague-Dawley rats were used to determine whether histories of responding maintained by drugs from different pharmacological classes (e.g., MDPV, cocaine, fentanyl, nicotine, or ketamine) would differentially impact the development of the high-responder phenotype when MDPV was available for self-administration. Two additional groups were used to determine whether noncontingent exposure to cocaine would prevent the development of the high-responder phenotype when MDPV was available for self-administration, and whether noncontingent exposure to MDPV would facilitate the development of the high-responder phenotype when cocaine was available for self-administration. Consistent with previous reports, a history of response-contingent cocaine, and to a lesser extent noncontingent cocaine, prevented the MDPV high-responder phenotype; however, when responding was initially maintained by fentanyl, nicotine, or ketamine, the MDPV high-responder phenotype developed in ∼45% of rats. By manipulating behavioral and pharmacological histories prior to evaluating MDPV self-administration, the current studies provide additional evidence that a history of response-contingent (or noncontingent) cocaine can prevent the transition from well regulated to aberrant drug-taking when responding is maintained by MDPV. Although the mechanism(s) that underlies this novel high-responder phenotype are unknown, elucidation may provide insight into individual differences relating to substance use disorder. SIGNIFICANCE STATEMENT: A subset of outbred Sprague-Dawley rats self-administer high levels of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Understanding the behavioral and/or pharmacological factors that can prevent the development of dysregulated MDPV self-administration may provide insight into individual differences in vulnerability to develop a substance use disorder.

Indexed as

Reinforcement ScheduleAdrenergic Uptake InhibitorsAnimalsBehavior, AddictiveBenzodioxolesCocaineFentanylKetamineMaleNicotinePyrrolidinesRatsRats, Sprague-DawleySelf AdministrationSynthetic CathinoneAdrenergic Uptake InhibitorsBenzodioxolesCocaineFentanylKetamineNicotinePyrrolidinesSynthetic Cathinone

Identifiers

PMID34413199
PMCPMC8626776

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.